Просмотр новости
Найдите то, что Вас интересует
Спутники
РН
SpaceX
Роскосмос
NASA
СпутникиРНSpaceXРоскосмосNASAIn their article, “Suzetrigine for Postoperative Pain in Head and Neck Free Flap or Transoral Robotic Surgery,” Bestourous et al use a retrospective cohort design to evaluate how adjunctive suzetrigine use affects postoperative opioid consumption. Their study included 146 patients undergoing head and neck free-flap reconstruction or transoral robotic surgery (TORS) at a single tertiary academic referral center. They found that suzetrigine was independently associated with significantly lower inpatient opioid requirements, demonstrated by an adjusted median difference of −76.4 morphine milligram equivalents compared with standard multimodal analgesia. Notably, postoperative pain scores remained similar between groups and no medication-related adverse events were identified. The authors conclude that selective peripheral NaV1.8 inhibition with suzetrigine represents a promising opioid-sparing strategy for complex otolaryngologic procedures that typically require substantial postoperative analgesia. The senior author (N.R.S.) of this Invited Commentary has held a long-standing interest in the future utilization of suzetrigine for postoperative pain management in otolaryngologic care. In this commentary, we seek to further contextualize the positive findings of this study across the breadth of otolaryngologic procedures and to provide some suggestions for targeted utilization of suzetrigine.